Bordetella Pertussis, Whooping Cough Clinical Trial
Official title:
EUpertstrain 4 Study of Bordetella Pertussis Isolates
This study focus on the genetic changes of B. pertussis clinical isolates. For this panels of B. pertussis isolates has been collected during four periods in different European countries.
B. pertussis is considered as a monomorphic pathogen. However, genetic changes have been
observed in several antigens (pertussis toxin, pertactin, filamentous haemagglutinin and
fimbriae) included in the current acellular pertussis vaccines between vaccine strains and
circulating isolates.
To study genetic changes in the B. pertussis populations in Europe, four distinct panels have
been collected: EUpert I in 1999-2001 including 102 isolates, EUpert II in 2004-2005
including 154 isolates, EUpert III in 2007-2009 including 140 isolates and EUpert IV in
2012-2015 including 265 isolates. Selection criteria have remained unchanged for all four
collections, which enables the opportunity to study changes in B. pertussis populations
during the last 15 years.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT05116241 -
Immunogenicity and Safety of BPZE1 Intranasal Pertussis Vaccine in Healthy School-age Children
|
Phase 2 | |
| Recruiting |
NCT05897879 -
Impact of Bacterial Expression and Immune Response in the Severity of Pertussis
|
N/A | |
| Completed |
NCT05461131 -
Pertussis Challenge Study in Adults Vaccinated With BPZE1
|
Phase 2 | |
| Completed |
NCT02983487 -
Pertussis Immunization Programs in Low Income Countries
|
||
| Completed |
NCT03388034 -
Pertussis Immunization Programs in Low Income Countries - Ivory Coast
|